Metformin is a widely used drug for the treatment of type 2 diabetes mellitus. Metformin activates AMP-activated protein kinase and suppresses lipogenic transcription factors such as sterol regulatory element binding protein-1 (SREBP-1). We investigated the effects of acute metformin treatment on the severity of acute myocardial infarction in both nondiabetic and diabetic mice. Mice were subjected to left anterior descending coronary artery occlusion (MI) for 30 min. followed by 24 hr. of reperfusion (R). Myocardial area-at-risk (AAR) was determined with in vivo Evans Blue dye injection and myocardial infarct size (INF) was measured using TTC staining. db/db diabetic mice and nondiabetic mice (10 weeks of age) were injected (i.p.) with metformin (0.25 mg/Kg) 18 hours before the onset of MI. Serum glucose levels were 94±6 mg/dL in nondiabetic mice and 323±16 mg/dL in db/db diabetic mice (p<0.01 between groups). Metformin treatment did not alter serum glucose levels at the time of MI. Data for myocardial infarct size in nondiabetic mice are shown in Figure 1 . Acute treatment with metformin significantly (p<0.001) reduced INF/AAR in nondiabetic mice. Data for myocardial infarct size in db/db diabetic mice treated with metformin are shown in Figure 2 . Metformin therapy also significantly (p<0.05) attenuated the extent of myocardial infarction in the db/db diabetic mouse heart. We conclude that acute metformin treatment protects against myocardial infarction in both nondiabetic and diabetic mice. Lei Ye, Husnain Kh Haider, Ruowen Ge, Peter K. Law, Terrance Chua, Salim Aziz, Eugene KW Sim, National University of Singapore, Singapore, Singapore, National University Medical Institute, Singapore, Singapore
Metformin is a widely used drug for the treatment of type 2 diabetes mellitus. Metformin activates AMP-activated protein kinase and suppresses lipogenic transcription factors such as sterol regulatory element binding protein-1 (SREBP-1). We investigated the effects of acute metformin treatment on the severity of acute myocardial infarction in both nondiabetic and diabetic mice. Mice were subjected to left anterior descending coronary artery occlusion (MI) for 30 min. followed by 24 hr. of reperfusion (R). Myocardial area-at-risk (AAR) was determined with in vivo Evans Blue dye injection and myocardial infarct size (INF) was measured using TTC staining. db/db diabetic mice and nondiabetic mice (10 weeks of age) were injected (i.p.) with metformin (0.25 mg/Kg) 18 hours before the onset of MI. Serum glucose levels were 94±6 mg/dL in nondiabetic mice and 323±16 mg/dL in db/db diabetic mice (p<0.01 between groups). Metformin treatment did not alter serum glucose levels at the time of MI. Data for myocardial infarct size in nondiabetic mice are shown in Figure 1 . Acute treatment with metformin significantly (p<0.001) reduced INF/AAR in nondiabetic mice. Data for myocardial infarct size in db/db diabetic mice treated with metformin are shown in Figure 2 . Metformin therapy also significantly (p<0.05) attenuated the extent of myocardial infarction in the db/db diabetic mouse heart. We conclude that acute metformin treatment protects against myocardial infarction in both nondiabetic and diabetic mice. Lei Ye, Husnain Kh Haider, Ruowen Ge, Peter K. Law, Terrance Chua, Salim Aziz, Eugene KW Sim, National University of Singapore, Singapore, Singapore, National University Medical Institute, Singapore, Singapore
Backgrounds
We hypothesized that synergy between VEGF 165 and angiopoietin-1 (Ang-1) by using a novel bicistronic vector encoding for two growth factors may lead to better prognosis when delivered using human myoblasts.
Methods
Human myoblasts carrying lac-z reporter gene were transduced with adenovirus carrying bicistronic vector encoding for human VEGF 165 and Ang-1. The transduced myoblasts were functionally assessed by immunostaining and RT-PCR. Myocardial infarction model was created in 17 female swines by coronary artery ligation and grouped as DMEM injected (group-1 n= 6), myoblast transplanted (group-2 n= 5), and myoblast carrying bicistronic vector (group-3 n=6). Three weeks later, 5 ml basal DMEM with 3x10 8 cells or without cells was injected intramyocardially in and around the infarct and immunosuppressed for six weeks using 5mg /kg cyclosporine. The animal was euthanized and the heart was explanted at 6-12 weeks post cell transplantation and processed for histological studies. p<0.01) respectively at 6 weeks post treatment. The mature blood vessels count in group-3 was the highest (94.6%). Regional blood flow (ml/min/g) at 6 weeks improved in group-3 (3.00± 0.37) significantly as compared to group-1 (1.22± 0.45 p<0.01) and group-2 (1.12± 0.14 p<0.01). The Ejection fraction in bicistronic group-3 was 43.0 ±10.4% which was significantly higher than the control group-1 (34.67±15.37, p<0.05).
Conclusion
Multiple growth factor gene delivery using myoblast as a carrier leads to angiomyogenesis with higher percentage of mature blood vessel formation. Cytokine assay showed an increase in myocardial IL-6 during I-R. To determine whether activated STAT3 could regulate ICAM-1 transcription in ECs, cultured human cardiac microvascular endothelial cells were exposed to IL-6, 40 ng/ml. Phosphorylated STAT3 was identified by immunoprecipitation within 15 min, and ICAM-1 mRNA increased shortly afterwards at 30 min after IL-6 exposure. Transfection of a GAS decoy oligonucleotide to inhibit STAT3 partially blocked IL6-induced ICAM-1 mRNA expression. The results indicate that STAT3 is activated very quickly in the myocardium following I-R, interacts with SP1 in the nucleus, and is responsible for rapid upregulation of ICAM-1 transcription.
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1116-4 Consequences of Hemodynamic Instability After Carotid Artery Stenting
Alex Abou-Chebl, Rishi Gupta, Christopher T. Bajzer, H. Christian Schumacher, Jay S. Yadav, The Cleveland Clinic Foundation, Cleveland, OH Purpose: To determine if hemodynamic instability (HI) during extracranial carotid artery stenting (CAS) increases the risk of adverse events. Background: CAS has been utilized in patients considered at high risk for carotid endarterectomy (CEA). HI is a known side effect of carotid sinus stimulation induced by CEA and CAS. Recent literature suggests that the presence of HI may increase the risk of adverse cardiovascular events following CEA, however the frequency and consequences of HI have not been systematically evaluated in a large population of patients undergoing CAS. Methods: Patients with HI were identified from the carotid stent registry maintained at The Cleveland Clinic Foundation. This is a prospectively collected database of all patients undergoing extracranial CAS for atherosclerotic lesions between 1999-2002. In addition, the medical records of all CAS patients were retrospectively reviewed to identify patients with peri-procedural HI who may have been missed by the database. HI was defined as symptomatic or asymptomatic hypotension (systolic blood pressure < 90) or braycardia (heart rate < 60). The use of vasopressors or atropine and all peri-procedural adverse events were study endpoints.
Results: A total of 404 consecutive patients with a mean age of 70.5 ± 9.8 yrs were studied. Sixty four percent were men. The mean stenosis severity was 85.6 ± 10.1%. Periprocedural hypotension occurred in 113 (28%) patients and required vasopressors in 85 % WOMEN IN POSTGRADUATE TRAINING (1992 -2001 
